BURLINGTON, Mass., Aug. 16, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Harlan F. Weisman, M.D., was elected to its board of directors at its Annual Meeting of Stockholders. Dr. Weisman brings over 20 years of experience as a senior healthcare executive and physician responsible for the development, regulatory approval and launch of innovative biopharmaceutical, medical device and diagnostic products. Dr. Weisman is the former Chief Science and Technology Officer for the Johnson & Johnson (J&J) Medical Devices and Diagnostics Group as well as former Company Group Chairman, Research & Development for Pharmaceuticals at J&J.
"We are very excited to have Dr. Weisman join Coronado's Board of Directors. He brings broad biotechnology and pharmaceutical industry experience, which includes involvement in, and supervision of, the development and approval of numerous drug products representing well over $10 billion in annual sales," commented Dr. Bobby W. Sandage, Jr., President and CEO of Coronado. "In particular, we believe that Dr. Weisman's extensive experience with the development of treatments for a variety of autoimmune diseases, will serve us well as we advance the development of TSO and CNDO-109."
Dr. Weisman is the Founder and Managing Director of And-One Consulting, LLC, a firm that assists life sciences companies develop global strategies aimed at accelerating medical product development, regulatory approval and market acceptance. Prior to his current position, Dr. Weisman was Chief Science and Technology Officer for Medical Devices and Diagnostics at J&J. In that role, he was a member of the Medical Devices and Diagnostics Group Operating Committee steering the group's scientific and technical agendas, including investments in group-level technologies, and sponsoring the research and development talent agenda. Before serving as Chief Science and Technology Officer for Medical Devices and Diagnostics, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals, where he had executive oversight of the ALZA Corporation, J&J Pharmaceutical Research and Development, and TransForm Pharmaceuticals, Inc. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Dr. Weisman was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine.
Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he did his post-graduate fellowship training in cardiovascular disease at Johns Hopkins Hospital.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.
The Coronado Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13033
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.